Menu Search
Equities

VolitionRX Ltd

VNRX:ASQ

VolitionRX Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.635
  • Today's Change0.021 / 3.39%
  • Shares traded36.18k
  • 1 Year change-39.52%
  • Beta1.1061
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year VolitionRX Ltd had net income fall 16.68% from a loss of 30.27m to a larger loss of 35.32m despite a 153.04% increase in revenues from 306.39k to 775.30k.
Gross margin--
Net profit margin-3,357.34%
Operating margin-3,355.65%
Return on assets-161.39%
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2023, VolitionRX Ltd increased its cash reserves by 90.76%, or 9.86m. Cash Flow from Financing totalled 28.98m or 3,738.25% of revenues. In addition the company used 18.06m for operations while cash used for investing totalled 1.08m.
Cash flow per share-0.3899
Price/Cash flow per share--
Book value per share-0.263
Tangible book value per share-0.267
More ▼

Balance sheet in USDView more

VolitionRX Ltd uses little or no debt in its capital structure.
Current ratio0.2371
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.